崔静达,韩江莉

• 1:北京大学第三医院心内科
• 2:北京大学第三医院全科医学科

摘要(Abstract)：

阿司匹林联合P2Y12受体抑制剂是预防急性冠状动脉综合征（ACS）经皮冠状动脉介入治疗后支架内血栓形成及全身动脉粥样硬化血栓事件的标准双联抗血小板治疗方案。ACS合并慢性肾病（CKD）患者血栓风险和出血发生率更高，因此，确定这一人群的最佳抗血小板药物治疗策略至关重要。既往大多数临床试验将晚期CKD患者排除在外，因而临床医师对这部分患者的抗血小板治疗策略缺乏循证医学证据。现综述ACS合并CKD患者抗血小板治疗研究进展，以期为临床医师面临此类患者时选择合适的抗血小板治疗策略提供借鉴。

关键词(KeyWords)： 急性冠状动脉综合征;慢性肾病;抗血小板治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 崔静达,韩江莉

参考文献(References)：

• [1]Lai AC,Bienstock SW,Sharma R,et al.A personalized approach to chronic kidney disease and cardiovascular disease:JACC review topic of the week[J].J Am Coll Cardiol,2021,77(11):1470-1479.DOI:10.1016/j.jacc.2021.01.028.
• [2]Fox CS,Muntner P,Chen AY,et al.Use of evidencebase d therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease:a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry[J].Circulation,2010,121(3):357-365.DOI:10.1161/CIRCULATIONAHA.109.865352.
• [3]Graham CA,Tan MK,Chew DP,et al.Use and outcomes of dual antiplatelet therapy for acute coronary syndrome inpatients with chronic kidney disease:insights from the Canadian Observational Antiplatelet Study(COAPT)[J].Heart Vessels,2022,37(8):1291-1298.DOI:10.1007/s00380-022-02029-8.
• [4]Byrne RA,Rossello X,Coughlan JJ,et al.2023 ESC Guidelines for the management of acute coronary syndromes[J].Eur Heart J,2023,44(38):3720-3826.DOI:10.1093/eurheartj/ehad 191.
• [5]Chen T,Deng Y,Gong R.Cardiovascular protection of aspirin in chronic kidney disease patients:an updated systematic review and Meta-analy sis[J].Curr Vasc Pharmacol,2023.DOI:10.2174/1570161121666230530154647.
• [6]Varian FL,Parker WAE,Fotheringham J,et al.Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease:releasing the evidence vacuum[J].Platelets,2023,34(1):2154330,DOI:10.1080/09537104.2022.2154330.
• [7]Stefanini GG,Briguori C,Cao D,et al.Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention:TWILIGHT-CKD[J].Eur Heart J,2021,42(45):4683-4693.DOI:10.1093/eurheartj/ehab533.
• [8]Schtipke S,Neumann FJ,Menichelli M,et al.Ticagrelor or prasugrel in patients with acute coronary syndromes[J].N Engl J Med,2019,381(16):1524-1534.DOI:10.1056/NEJMoa1908973.
• [9]Bonello L,Angiolillo DJ,Aradi D,et al.P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes[J].Circulation,2018,138(15):1582-1596.DOI:10,1161/CIRCULATIONAHA,118.032078.
• [10]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.DOI:10.1056/NEJMoa0904327.
• [11]Wiviott SD,Braunwald E,McCabe CH,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015.DOI:10.1056/NEJMoa0706482.
• [12]Costa F,van Klaveren D,James S,et al.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT)score:a pooled analysis of individual-patient datasets from clinical trials[J].Lancet,2017,389(10073):1025-1034.DOI:10.1016/S0140-6736(17)30397-5.
• [13]Urban P,Mehran R,Colleran R,et al.Defining high bleeding risk in patients undergoing percutaneous coronary intervention[J].Circulation,2019,140(3):240-261.DOI:10.1161/CIRCULATIONAHA.119.040167.
• [14]Kadiyala V,Long S,Has P,et al.PRECISE-DAPT and ARCHBR predict in-hospital outcomes in patients who underwent percutaneous coronary intervention[J].Am J Cardiol,2023,191:43-50.DOI:10.1016/j.amjcard.2022.12.004.
• [15]Matsumoto T,Saito Y,Sato T,et al.Diagnostic ability of Japanese version of high bleeding risk criteria for ischemic outcomes in patients with acute myocardial infarction[J],Heart Vessels,2023.DOI:10.1007/s00380-023-02303-3.
• [16]Yanqiao L,Shen L,Yutong M,et al.Comparison of GRACE and TIMI risk scores in the prediction of in-hospital and longterm outcomes among East Asian non-ST-elevation myocardial infarction patients[J].BMC Cardiovasc Disord,2022,22(1):4.DOI:10.1186/s12872-021-02311-z.
• [17]Yamashita D,Saito Y,Sato T,et al.Impact of PARIS and CREDO-Kyoto thrombotic and bleeding risk scores on clinical outcomes in patients with acute myocardial infarction[J].Circ J,2022,86(4):622-629.DOI:10.1253/circj.CJ-21-0556.
• [18]吴智健,周志鹏,吴延庆.冠状动脉支架置入术后双联抗血小板治疗最佳疗程研究进展[J].中国介入心脏病学杂志,2021,29(12):698-703.DOI:10.3969/j.issn.1004-8812.2021.12.009.
• [19]De Servi S,Landi A,Savonitto S,et al.Antiplatelet strategies for older patients with acute coronary syndromes:finding directions in a low-evidence field[J].J Clin Med,2023,12(5):2082.DOI:10.3390/jcm12052082.
• [20]Mavrakanas TA,Chatzizisis YS,Gariani K,et al.Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents:a Meta-analysis[J].Clin J Am Soc Nephrol,2019,14(6):810-822.DOI:10.2215/CJN.12901018.
• [21]Yu Y,Pan D,Bai R,et al,P2Y12 inhibitor monotherapy after1-3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention:a meta-analysis of randomized controlled trials[J].Front Cardiovasc Med,2023,10:1197161.DOI:10.3 389/fcvm.2023.1197161.
• [22]Escaned J,Cao D,Baber U,et al.Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention:TWILIGHT-HBR[J].Eur Heart J,2021,42(45):4624-4634.DOI:10.1093/eurheartj/ehab702.
• [23]Hahn JY,Song YB,Oh JH,et al.Effect of P2Y12 inhibitor monotherapy vs.dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized clinical trial[J].JAMA,2019,321(24):2428-2437.DOI:10.1001/jama.2019.8146.
• [24]Valgimigli M,Smits PC,Frigoli E,et al.Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk:a MASTER DAPT trial sub-analysis[J].Eur Heart J,2022,43(33):3100-3114.DOI:10.1093/eurheartj/ehac284.
• [25]Guimaraes PO,Franken M,Tavares CAM,et al.P 2 Y_(12)inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting:rationale and design of the NEOMINDSET Trial[J].Euro Intervention,2023,19(4):e323-e329.DOI:10.4244/EIJ-D-23-00125.
• [26]Yeh CH,Chung WJ,Chen TY,et al.The impact of FEV1/FVC ratio on the clinical outcomes in acute coronary syndrome patients treated with dual anti-platelet agents[J].Acta Cardiol Sin,2023,39(1):116-126.DOI:10.6515/ACS.202301 39(1).20220601A.
• [27]Angiolillo DJ,Bernardo E,Capodanno D,et al.Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy[J].J Am Coll Cardiol,2010,55(11):1139-1146.DOI:10.1016/j.j acc.2009.10.043.
• [28]Wu Y,Song Y,Pan Y,Gong Y,et al.High on-clopidogrel platelet reactivity and chronic kidney disease:a meta-analysis of literature studies[J].Scand Cardiovasc J,2019,53(2):55-61.DOI:10.1080/14017431,2019.1598571.
• [29]Claassens DMF,Vos GJA,Bergmeijer TO,et al.A genotypeguided strategy for oral P2Y12 inhibitors in primary PCI[J].N Engl J Med,2019,381(17):1621-1631.DOI:10.1056/NEJMoa1907096.
• [30]Sibbing D,Gross L,Trenk D,et al.Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention:results from the randomized TROPICAL-ACS trial[J].Eur Heart J,2018,39(29):2749-2758.DOI:10.109 3/eurheartj/ehy3 32.
• [31]Galli M,Benenati S,Capodanno D,et al.Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention:a systematic review and meta-analysis[J].Lancet,2021,397(10283):1470-1483.DOI:10.1016/S0140-6736(21)00533-X,
• [32]Kao CC,Wu MS,Chuang MT,et al.Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease[J].PLoS One,2021,16(8):e0255645.DOI:10.1371/journal.pone.0255645.
• [33]Szummer K,Lindnagen L,Evans M,et al.Treatments and mortality trends in cases with and without dialysis who have an acute myocardial infarction:an 18-year nationwide experience[J].Circ Cardiovasc Qual Outcomes,2019,12(9):e005 879.DOI:10.1161/CIRCOUTCOMES.119.005879.
• [34]Edfors R,Sahlen A,Szummer K,et al.Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function[J].Heart,2018,104(19):1575-1582.DOI:10.1136/heartjnl-2017-312436.
• [35]Chen YT,Chen HT,Hsu CY,et al.Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis[J].Clin J Am Soc Nephrol,2017,12(2):262-271.DOI:10.2215/CJN.04430416.